Longitude Capital
Longitude Capital invests in transformative healthcare companies—biotechnology, medical technology, and health solutions—that improve clinical outcomes, enhance patient quality of life, and reduce cost of care through venture growth investments in clinically de-risked, commercially-staged assets.
Investment thesis
Longitude Capital invests in transformative healthcare companies—biotechnology, medical technology, and health solutions—that improve clinical outcomes, enhance patient quality of life, and reduce cost of care through venture growth investments in clinically de-risked, commercially-staged assets.
Partners
Managing Director, Founder
Managing Director
Managing Director, Founder
Managing Director, Chief Financial Officer
What sets Longitude Capital apart
- 200+ years combined life sciences investing experience across team
- 18+ year track record since 2006 with $2B+ deployed across six funds
- Dual-office structure (Menlo Park, Boston) providing coast-to-coast medtech/biotech coverage
- Executive operating experience embedded (Roche, Novartis, Cardinal Health, GRAIL CFO, Jazz CFO)
Recent investments
CG Oncology (CGON), Alpha-9 Oncology, OrsoBio, Aviceda Therapeutics
Investment profile
- Stages
- Clinical stage, Commercial stage, Growth, Late stage
- Sectors
- Biotechnology, Medical technology, Health solutions, Diagnostics, Surgical devices, Therapeutics
- Cold inbound
- Warm intro preferred
Frequently asked questions
- What does Longitude Capital invest in?
- Longitude Capital is a clinical stage, commercial stage, growth, late stage stage Biotechnology, Medical technology, Health solutions, Diagnostics, Surgical devices, Therapeutics investor, primarily investing in US. Their thesis: Longitude Capital invests in transformative healthcare companies—biotechnology, medical technology, and health solutions—that improve clinical outcomes, enhance patient quality of life, and reduce cost of care through venture growth investments in clinically de-risked, commercially-staged assets.
- Is Longitude Capital actively deploying capital?
- Longitude Capital is actively deploying capital. What we observed: Fund raised $2B+ across six funds since 2006 with continuous board activity through 2024 across multiple portfolio companies; active board members and recent hires (Matthew Young 2022, Neil Advani 2024) indicate ongoing deployment.
- What makes Longitude Capital different from other funds?
- Longitude Capital stands out on 4 points: 200+ years combined life sciences investing experience across team; 18+ year track record since 2006 with $2B+ deployed across six funds; Dual-office structure (Menlo Park, Boston) providing coast-to-coast medtech/biotech coverage; Executive operating experience embedded (Roche, Novartis, Cardinal Health, GRAIL CFO, Jazz CFO).
- What has Longitude Capital invested in recently?
- Recent investments DryPowder has tracked from Longitude Capital include CG Oncology (CGON), Alpha-9 Oncology, OrsoBio, Aviceda Therapeutics.
- How do I reach out to Longitude Capital?
- Longitude Capital doesn't generally take cold inbound — a warm introduction from a founder or investor they already know is the reliable path in. Use DryPowder's AI fund matching to see how your startup aligns with Longitude Capital's thesis and focus areas (Biotechnology, Medical technology, Health solutions, Diagnostics, Surgical devices, Therapeutics) — it returns a fit score and specific talking points for your outreach.